中国临床药理学杂志2018，Vol.34Issue(19)：2283-2286,4.DOI:10.13699/j.cnki.1001-6821.2018.19.012
艾拉莫德片联合雷公藤多苷片治疗活动期老年类风湿关节炎的临床研究
Clinical trial iguratimod tablets combined with tripterysium glycosides tablets in the treatment of elderly patients with active rheumatoid arthritis
摘要
Abstract
Objective To observe the clinical efficacy and safety of igu-ratimod tablets combined with tripterysium glycosides tablets in the treat-ment of elderly patients with active rheumatoid arthritis ( RA).Methods A total of 90 elderly patients with active RA were randomly divided in-to control and treatment groups with 45 cases per group.Control group was given tripterysium glycosides 20 mg per time, tid, orally.Treatment group was given iguratimod 25 mg per time, bid, orally, on the basis of control group.Two groups were treated for 24 weeks.The clinical effica-cy, the levels of erythrocyte sedimentation rate (ESR), C-reactive pro-tein(CRP) and rheumatoid factor(RF), and adverse drug reactions were compared between two groups.Results Compared with treatment group and control groups after treatment , the effective rates of ACR20 were 86.67%(39 cases /45 cases) and 46.67%(21 cases /45 cases), the effective rates of ACR50 were 68.89%(31 cases /45 cases) and 31.11%(14 cases /45 cases), the effective rates of ACR70 were 24.44%(11 cases /45 cases) and 6.67%(3 ca-ses /45 cases), the differences were statistically significant (all P<0.05).After treatment, the main indexes of treatment and control groups were compared : ESR were (16.42 ±9.87 ) and (23.36 ±10.16 ) mm· h-1, CRP were (6.59 ±4.05) and (11.42 ±6.64)mg· L-1, RF were (50.06 ±15.49) and (61.34 ±22.30)U· mL-1, the diffe-rences were statistically significant ( all P<0.05).The adverse drug reactions of two groups were leukopenia , elevated liver transaminase and epigastric discomfort .The total incidences of adverse drug reactions in treatment and control groups were 13.33%and 11.11% without significant difference ( P>0.05 ).Conclusion Iguratimod tablets com-bined with tripterysium glycosides tablets have a definitive clinical efficacy in the treatment of elderly patients with ac -tive RA, which is better than tripterysium glycosides alone , without increasing the incidence of adverse drug reactions .关键词
艾拉莫德片/雷公藤多苷片/活动期老年类风湿关节炎/安全性评价Key words
iguratimod tablet/tripterysium glycosides tablet/elderly patients with active rheumatoid arthritis/safety evaluation分类
医药卫生引用本文复制引用
刘媛媛,沈海丽..艾拉莫德片联合雷公藤多苷片治疗活动期老年类风湿关节炎的临床研究[J].中国临床药理学杂志,2018,34(19):2283-2286,4.基金项目
兰州市科学技术局基金资助项目(2017-4-89) （2017-4-89）
